These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24792335)

  • 1. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.
    Kim ES; Tang X; Peterson DR; Kilari D; Chow CW; Fujimoto J; Kalhor N; Swisher SG; Stewart DJ; Wistuba II; Siddik ZH
    Lung Cancer; 2014 Jul; 85(1):88-93. PubMed ID: 24792335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of Expression Levels of Copper Transporter 1 and Thymidylate Synthase with Treatment Outcomes in Patients with Advanced Non-small Cell Lung Cancer Treated with S-1/Carboplatin Doublet Chemotherapy.
    Konishi M; Imai A; Fujii M; Sugimoto K; Katakami N; Imai Y; Kamoshida S
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):435-441. PubMed ID: 29479997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.
    Xu X; Duan L; Zhou B; Ma R; Zhou H; Liu Z
    Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):786-92. PubMed ID: 22725681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
    Jiang P; Wu X; Wang X; Huang W; Feng Q
    Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
    Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
    Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop.
    Zhang W; Shi H; Chen C; Ren K; Xu Y; Liu X; He L
    Phytomedicine; 2018 Sep; 48():51-61. PubMed ID: 30195880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
    Blair BG; Larson CA; Safaei R; Howell SB
    Clin Cancer Res; 2009 Jul; 15(13):4312-21. PubMed ID: 19509135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the Copper Transporter Protein 1 (CTR1) Polymorphism on Adverse Events among Advanced NonSmall Cell Lung Cancer Patients Treated with a Carboplatin/Gemcitabine Regimen.
    Kumpiro S; Sriuranpong V; Areepium N
    Asian Pac J Cancer Prev; 2016; 17(9):4391-4394. PubMed ID: 27797249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue platinum concentration and tumor response in non-small-cell lung cancer.
    Kim ES; Lee JJ; He G; Chow CW; Fujimoto J; Kalhor N; Swisher SG; Wistuba II; Stewart DJ; Siddik ZH
    J Clin Oncol; 2012 Sep; 30(27):3345-52. PubMed ID: 22891266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose restriction induces ROS-AMPK-mediated CTR1 expression and increases cisplatin efficiency in NSCLC.
    Zhang P; Li B; Chen Q; Wang H; Feng Q
    Cancer Lett; 2022 Sep; 543():215793. PubMed ID: 35716782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients.
    Xu X; Ren H; Zhou B; Zhao Y; Yuan R; Ma R; Zhou H; Liu Z
    Lung Cancer; 2012 Aug; 77(2):438-42. PubMed ID: 22516052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
    Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
    Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
    Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
    Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research progress of copper transporter 1 in platinum-based chemotherapy].
    Ouyang Q; Liu Y; Liu Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 43(12):1376-1379. PubMed ID: 30643056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.
    Chen HH; Yan JJ; Chen WC; Kuo MT; Lai YH; Lai WW; Liu HS; Su WC
    Lung Cancer; 2012 Feb; 75(2):228-34. PubMed ID: 21788094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).
    Li ZH; Qiu MZ; Zeng ZL; Luo HY; Wu WJ; Wang F; Wang ZQ; Zhang DS; Li YH; Xu RH
    J Transl Med; 2012 Feb; 10():21. PubMed ID: 22304828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEAT1 acts as an inducer of cancer stem cell-like phenotypes in NSCLC by inhibiting EGCG-upregulated CTR1.
    Jiang P; Chen A; Wu X; Zhou M; Ul Haq I; Mariyam Z; Feng Q
    J Cell Physiol; 2018 Jun; 233(6):4852-4863. PubMed ID: 29152741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
    Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
    World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.